Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 14, 2026

Kevin Warsh Is the New Fed Chair and Rates May Not Drop This Year. Here's What That Means for Your Portfolio.

View original at finance.yahoo.com
Kevin Warsh Is the New Fed Chair and Rates May Not Drop This Year. Here's What That Means for Your Portfolio. The Trump administration faced its fair share of obstacles in getting Kevin Warsh approved as the new chair of the Federal Reserve, but they have officially crossed the finish line…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The current federal funds rate of 3.50%-3.75% is low relative to many decades of history but high relative to the past 20 years

    60% confidence
  • Warsh faces the task of appeasing President Trump, dealing with a divided FOMC, and navigating a difficult economy in pursuit of the Fed's dual mandate

    60% confidence
  • The conflict in Iran could keep gas prices high for at least the next several months

    60% confidence
  • Following April economic data, it seems unlikely the Fed will be able to cut interest rates this year or possibly next year

    60% confidence
  • Lower interest rates have historically been more supportive of higher stock prices due to economic stimulus, higher DCF valuations, and reduced appeal of bonds

    60% confidence
  • The market does not expect the Fed to cut rates this year (2026) or in 2027

    60% confidence
  • When bond yields are lower, future cash flows in DCF models are higher, leading to higher stock valuations; when yields are higher, future cash flows are lower

    60% confidence
  • There is a higher probability that the Fed will raise interest rates rather than cut them toward the end of 2027

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com